Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac N.V (CVAC) EBITDA: 2019-2025

Historic EBITDA for CureVac N.V (CVAC) over the last 4 years, with Jun 2025 value amounting to -$345,248.

  • CureVac N.V's EBITDA rose 99.56% to -$345,248 in Q2 2025 from the same period last year, while for Jun 2025 it was -$405,573, marking a year-over-year increase of 99.80%. This contributed to the annual value of $189.9 million for FY2024, which is 164.36% up from last year.
  • Latest data reveals that CureVac N.V reported EBITDA of -$345,248 as of Q2 2025, which was down 343.54% from -$77,839 recorded in Q1 2025.
  • In the past 5 years, CureVac N.V's EBITDA ranged from a high of $41,675 in Q4 2024 and a low of -$137.1 million during Q1 2021.
  • For the 3-year period, CureVac N.V's EBITDA averaged around -$34.3 million, with its median value being -$26.7 million (2023).
  • As far as peak fluctuations go, CureVac N.V's EBITDA slumped by 813,282.49% in 2022, and later surged by 157.81% in 2024.
  • Quarterly analysis of 5 years shows CureVac N.V's EBITDA stood at -$38,895 in 2021, then slumped by 264.61% to -$141,814 in 2022, then spiked by 49.17% to -$72,088 in 2023, then spiked by 157.81% to $41,675 in 2024, then skyrocketed by 99.56% to -$345,248 in 2025.
  • Its EBITDA stands at -$345,248 for Q2 2025, versus -$77,839 for Q1 2025 and $41,675 for Q4 2024.